ASCENTAGE PHARMA ANNOUNCES INCLUSION OF LISAFTOCLAX IN CHINA'S 2026 NATIONAL REIMBURSEMENT DRUG LIST AND SUCCESSFUL RENEWAL OF COVERAGE FOR OLVEREMBATINIB

Reuters · 1d ago

Please log in to view news